New research at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is using artificial intelligence (AI) to devise new ways of predicting which patients will develop an aggressive and difficult-to-detect form of breast cancer called lobular cancer, which represents one in every 10 breast cancers diagnosed in the United States.

Metaplastic breast carcinoma, a rare entity (<1% of breast neoplasms), lacks comprehensive spectroscopic characterization. This study aimed to address this gap by providing a qualitative and quantitative spectroscopic profile of metaplastic carcinoma in comparison to ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC).

Results from the health-related quality of life (HRQOL) analysis of the University of Pennsylvania and RTOG Foundation RadComp study indicated that both photon and proton radiation treatment options yielded similar, excellent HRQOL outcomes for women with non-metastatic breast cancer. RadComp was the first randomized study comparing proton to photon radiation for breast cancer treatment.

Breast cancer survivors with severe menopausal symptoms should be supported to make an informed decision about whether to have hormone replacement therapy or not, according to an interdisciplinary panel of experts including researchers from UCL.

The first randomized trial to compare photon- and proton-based radiation therapy for breast cancer finds that patients report equally strong health-related quality of life with either treatment. Patients who received proton therapy were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar. First results of the phase III Radiotherapy Comparative Effectiveness (RadComp) trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.